JP2024517431A5 - - Google Patents

Info

Publication number
JP2024517431A5
JP2024517431A5 JP2023565206A JP2023565206A JP2024517431A5 JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5 JP 2023565206 A JP2023565206 A JP 2023565206A JP 2023565206 A JP2023565206 A JP 2023565206A JP 2024517431 A5 JP2024517431 A5 JP 2024517431A5
Authority
JP
Japan
Prior art keywords
ray powder
powder diffraction
solid
exhibiting
solid form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023565206A
Other languages
English (en)
Japanese (ja)
Other versions
JP7825636B2 (ja
JP2024517431A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/025815 external-priority patent/WO2022226221A1/en
Publication of JP2024517431A publication Critical patent/JP2024517431A/ja
Publication of JP2024517431A5 publication Critical patent/JP2024517431A5/ja
Application granted granted Critical
Publication of JP7825636B2 publication Critical patent/JP7825636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023565206A 2021-04-23 2022-04-21 (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態 Active JP7825636B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
US63/178,752 2021-04-23
PCT/US2022/025815 WO2022226221A1 (en) 2021-04-23 2022-04-21 Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof

Publications (3)

Publication Number Publication Date
JP2024517431A JP2024517431A (ja) 2024-04-22
JP2024517431A5 true JP2024517431A5 (cg-RX-API-DMAC7.html) 2025-05-02
JP7825636B2 JP7825636B2 (ja) 2026-03-06

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565206A Active JP7825636B2 (ja) 2021-04-23 2022-04-21 (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Country Status (12)

Country Link
US (1) US12692248B2 (cg-RX-API-DMAC7.html)
EP (1) EP4326255A4 (cg-RX-API-DMAC7.html)
JP (1) JP7825636B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240000540A (cg-RX-API-DMAC7.html)
CN (1) CN117529313A (cg-RX-API-DMAC7.html)
AU (1) AU2022261159A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021916A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216258A1 (cg-RX-API-DMAC7.html)
IL (1) IL307910A (cg-RX-API-DMAC7.html)
MX (1) MX2023012521A (cg-RX-API-DMAC7.html)
TW (1) TWI922665B (cg-RX-API-DMAC7.html)
WO (1) WO2022226221A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6636014B2 (ja) 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
CA3107014A1 (en) 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
JP2022525885A (ja) * 2019-03-22 2022-05-20 キネート バイオファーマ インク. Rafキナーゼの阻害剤
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Similar Documents

Publication Publication Date Title
AU652046B2 (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present
JP4931874B2 (ja) リモナバントの結晶多形の製造方法
US20090092669A1 (en) Stable imatinib compositions
US10189860B2 (en) Hydrates of dolutegravir sodium
JP2018168180A (ja) バルサルタンおよびahu−377を含む三ナトリウム塩超分子複合体の新規な結晶形及びその製造方法
US20100010098A1 (en) Polymorphs of rasagiline hydrochloride
WO1996036595A1 (en) 3,4-disubstituted-phenylsulphonamides and their therapeutic use
EP1286670A2 (en) Use of therapeutic benzamide derivatives
JP7825636B2 (ja) (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
JP2022532404A5 (cg-RX-API-DMAC7.html)
KR20100126238A (ko) N,n-디메틸 이미도디카르본이미딕 디아미드의 디카르복실산염, 그의 제조 방법 및 그의 약제학적 조성물
JP2023548160A (ja) 1-(3-シアノ-1-イソプロピル-インドール-5-イル)ピラゾール-4-カルボン酸の結晶性粒子の製造方法およびそれを含む薬学的組成物
JP2000500732A (ja) 2−(4−置換)−ベンジルアミノ−2−メチル−プロパンアミド誘導体
CA2483597A1 (en) New pharmaceutical compositions containing flibanserin polymorph a
CN116869915A (zh) 含有苯并咪唑衍生物的新型制剂
JP2007509143A5 (cg-RX-API-DMAC7.html)
PL183867B1 (pl) Nowe indazolokarboksyamidy, sposób ich wytwarzania i środek farmaceutyczny
AU2017254950B2 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
JP4278652B2 (ja) 結晶性シブトラミンメタンスルホン酸塩半水和物を含む医薬組成物
JP2021529805A5 (cg-RX-API-DMAC7.html)
TW200900392A (en) Novel crystalline bepotastine metal salt hydrate, method for preparing same, and pharmaceutical composition comprising same
JP2024542840A5 (cg-RX-API-DMAC7.html)
HUP0402553A2 (hu) Venlafaxin-hidroklorid-monohidrát, eljárások előállítására, az ezt tartalmazó gyógyszerkészítmények és alkalmazásuk
JP7226697B2 (ja) ブロナンセリン含有錠剤
JP7628020B2 (ja) アキシチニブを有効成分とする医薬錠剤